Bloomberg
Sellas Life Sciences Stock Triples After Cancer Vaccine Data
Tuesday, November 17, 2026
Sellas Life Sciences Group Inc. reported positive results from a late-stage trial of an experimental cancer vaccine designed to treat an aggressive form of blood cancer. The company's stock price tripled following the announcement. Specific efficacy data, patient numbers, and the vaccine's mechanism were not provided in the available information.
Original reporting:
